


04-17-06

ifn



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Shailubhai et al.
SERIAL NUMBER: 10/796,292 EXAMINER : Cybille Delacroix Muirhe
FILING DATE: March 10, 2004 ART UNIT : 1614
FOR: METHOD OF TREATING CANCER WITH AZASPIRANE
COMPOSITIONS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages);
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited References: B1; C2-6; and
4. Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 33357-501. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, Reg. No. 38,384
Gregory J. Sieczkiewicz, Reg. No. 48,223
Attorneys for Applicant
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: April 13, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Shailubhai et al.
SERIAL NUMBER: 10/796,292 EXAMINER : Cybille Delacroix Muirhe
FILING DATE: March 10, 2004 ART UNIT : 1614
FOR: METHOD OF TREATING CANCER WITH AZASPIRANE
COMPOSITIONS

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed within three months of the mailing date of the Supplementary European Search Report for EP 04 71 9198, mailed March 8, 2006 in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplementary Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Shailubhai et al.
U.S.S.N.: 10/796,292

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 33357-501.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, Reg. No. 38,384
Gregory J. Sieczkiewicz, Reg. No. 48,223
Attorneys for Applicant
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: April 13, 2006

TRA 2141681v.1

Express Mail No.: EV 460337493 US
Date of Deposit: April 13, 2006



Page 1 of 1
Attorney Docket No.: 33357-501

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/796,292	
				Filing Date		March 10, 2004	
				First Named Inventor		Shailubhai	
				Group Art Unit		1614	
				Examiner Name		Cybille Delacroix Muirhe	
				Attorney Docket Number		33357-501	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	EP 0 753 512 A1		SMITHKLINE BEECHAM CORPORATION	01/15/97		

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C2	Mirabelli et al. <i>Anti-Cancer Drug Design</i> , 3(4):231-242 (1989)
	C3	Rice et al. <i>J. Med. Chem.</i> , 43:388-402 (1963)
	C4	Rice et al. <i>J. Med. Chem.</i> , 11(2):378-380 (1968)
	C5	Rice et al. <i>J. Heterocyclic Chem.</i> , 10(5):731-735 (1973)
	C6	Supplementary European Search Report for EP 04 71 9198, mailed March 8, 2006.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.